New study identifies biological mechanism driving therapy resistance in advanced prostate cancer

A multi-institutional study led by researchers at the University of Chicago and the Fred Hutchinson Cancer Center has identified a specific transfer RNA molecule, tRNAArg (UCU)-1, as a key factor in the development of therapy resistance in advanced prostate cancer. Published in Nature, the research reveals that depletion of tRNAArg (UCU)-1 allows prostate cancer cells to escape targeted therapies and transition into more aggressive forms of the disease.

This discovery could potentially lead to the development of strategies to resensitize treatment-resistant tumors to existing therapies. The study, published in Nature, sheds light on the molecular mechanisms behind lineage plasticity, a process where cancer cells lose dependence on androgen signaling and acquire features of neuroendocrine prostate cancer, which is resistant to therapy.

Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.